.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Medtronic
McKinsey
Citi
Merck
UBS
Moodys
Boehringer Ingelheim
Farmers Insurance
Chubb

Generated: December 15, 2017

DrugPatentWatch Database Preview

Patents Expiring in August 2018

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
CelgeneTHALOMIDthalidomideCAPSULE;ORAL020785-002Jan 17, 2003RXYesNo► Subscribe► SubscribeAPPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
CelgeneTHALOMIDthalidomideCAPSULE;ORAL020785-003Jan 17, 2003RXYesYes► Subscribe► SubscribeAPPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)
CelgeneTHALOMIDthalidomideCAPSULE;ORAL020785-003Jan 17, 2003RXYesYes► Subscribe► SubscribeMETHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-001Dec 27, 2005RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
CelgenePOMALYSTpomalidomideCAPSULE;ORAL204026-001Feb 8, 2013RXYesNo► Subscribe► SubscribeUSE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
CelgeneTHALOMIDthalidomideCAPSULE;ORAL020785-002Jan 17, 2003RXYesNo► Subscribe► SubscribeUSE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
CelgeneREVLIMIDlenalidomideCAPSULE;ORAL021880-006Jun 5, 2013RXYesNo► Subscribe► SubscribeUSE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
CelgenePOMALYSTpomalidomideCAPSULE;ORAL204026-004Feb 8, 2013RXYesYes► Subscribe► SubscribeUSE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
CelgeneTHALOMIDthalidomideCAPSULE;ORAL020785-003Jan 17, 2003RXYesYes► Subscribe► SubscribeTREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
CelgeneTHALOMIDthalidomideCAPSULE;ORAL020785-001Jul 16, 1998RXYesNo► Subscribe► SubscribeUSE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Deloitte
Daiichi Sankyo
Boehringer Ingelheim
AstraZeneca
Colorcon
Johnson and Johnson
QuintilesIMS
Medtronic
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot